Sp748
MICROBE-MICROBE INTERACTIONS PROMOTE C. DIFFICILE INFECTION
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
The gastrointestinal tract is a diverse and complex ecosystem shaped by continual interactions between host cells, nutrients, and the gut microbiota. Under homeostatic conditions, the human gut microbiota limits the growth of pathogenic bacteria and restricts the influence of resident pathobionts. However, when the gut microbiota network is disrupted, pathobionts and pathogens can colonize and cause disease. This session focuses on factors which influence the colonization of Clostridioides difficile and other gut pathobionts.
The gastrointestinal tract is a diverse and complex ecosystem shaped by continual interactions between host cells, nutrients, and the gut microbiota. Under homeostatic conditions, the human gut microbiota limits the growth of pathogenic bacteria and restricts the influence of resident pathobionts. However, when the gut microbiota network is disrupted, pathobionts and pathogens can colonize and cause disease. This session focuses on factors which influence the colonization of Clostridioides difficile and other gut pathobionts.
Presenter
Medical University of South Carolina
Tracks
Related Products
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AGA Genetics and Gastrointestinal Disorders
This session will provide the latest progress in genetics-related developmental GI research…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
